• Jupiter Neurosciences began enrolling patients in the Phase 2a RESET trial testing oral JOTROL in Parkinson’s disease.
• Results have not been presented; first patient dosing is expected soon, with study completion projected in H1 2027.
• The study aims to assess whether JOTROL can be used safely in patients while supporting its potential as a disease-modifying approach.
• Management highlighted Parkinson’s as a market without approved disease-modifying therapies, with the global treatment market at USD 5.65 billion in 2024.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Jupiter Neurosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202605270730PRIMZONEFULLFEED9727286) on May 27, 2026, and is solely responsible for the information contained therein.